Inhibitors of JAK2/STAT Signaling Pathway and Hematologic Malignancies-Review.
10.7534/j.issn.1009-2137.2016.04.059
- Author:
Ya-Ling ZHAO
1
,
2
;
Gui-Min LIU
1
;
Li-Jun ZHANG
1
;
Wen-Tong LIANG
3
;
Zhi-Yong CHENG
4
Author Information
1. Department of Hematology, Baoding Municipal First Hospital, Baoding 071000, Hebei Province, China
2. Department of Medical Dingzhou People's Hospital, Dingzhou 073000, Hebei Province, China.
3. Department of Hematology, Baoding Municipal First Hospital, Baoding 071000, Hebei Province, China.E-mail: liangwentong1967@sina.com.
4. Department of Hematology, Baoding Municipal First Hospital, Baoding 071000, Hebei Province, China.E-mail:dzczy@sohu.com.
- Publication Type:Journal Article
- MeSH:
Hematologic Neoplasms;
Humans;
Janus Kinase 2;
Mutation;
STAT Transcription Factors;
Signal Transduction
- From:
Journal of Experimental Hematology
2016;24(4):1275-1279
- CountryChina
- Language:Chinese
-
Abstract:
Jauns kinase (JAK)/transducer and activator of transcription（STAT） pathway is a classical approach to study the rapid changes of the gene expression in specific target cells by a variety of extracellular signals. The JAK and STAT transfer cytokine receptor signaling plays a unique role in multiple cellular and molecular biological changes.The abnormal signal of JAK/STAT pathway will lead to the hematopoietic abnormalities.Studies had shown that the abnormal activation of JAK2/STAT signaling pathway are in many kinds of malignant hematological diseases, such as in acute lymphoblastic/myeloid leukemia, chronic myeloid leukemia, lymphoma, myelodysplastic syndromes, myeloprofilerative neoplasm, especially in the patients of myeloproliferative neoplasm(MPN) with JAK gene mutation(JAK2V617F), this mutation has an important value for MPN diagnosis. At present, the effect of the specific inhibitors of JAK2 has showed good perspective, which had been applied to clinic treatment and achieved remarkable curative effect. In this review, the JAK2/STAT signaling transduction, the JAK2 signal and hematologic malignancies, the kagulation of signaling pathway and the inhibitors of JAK2/STAT signaling pathway are summarized.
